The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.
High-volume centres achieve excellent long-term survival and low reoperation rates in mitral valve repair—key findings ...
The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback